Viewing Study NCT04416412


Ignite Creation Date: 2025-12-26 @ 11:13 PM
Ignite Modification Date: 2026-03-19 @ 7:56 PM
Study NCT ID: NCT04416412
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-05-01
First Post: 2020-05-21
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: ICG Fluorescence Imaging in Open Fracture Trauma Patients
Sponsor: Dartmouth-Hitchcock Medical Center
Organization:

Study Overview

Official Title: Optimizing Surgical Debridement Following High-energy Open Trauma With Dynamic Contrast-enhanced Fluorescence Imaging
Status: ACTIVE_NOT_RECRUITING
Status Verified Date: 2025-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is a prospective observational study that will evaluate the association between bone and tissue perfusion, as measured by indocyanine green (ICG) fluorescence imaging, and complications, in an effort to develop ICG fluorescence imaging as a diagnostic tool to quantitatively guide operative debridement.
Detailed Description: This is a prospective observational study that will evaluate the association between bone and tissue perfusion, as measured using indocyanine green (ICG) fluorescence imaging, and complications. This will be used to develop ICG fluorescence imaging as a diagnostic tool to objectively and quantitatively guide operative debridement. The study population includes all open fracture patients regardless of race, ethnicity, or sex/gender. Primary outcome measure is all-cause re-operation and secondary outcome measure is surgical site infection. All patients will be followed for a total of 12 months.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
OR190062 OTHER_GRANT Department of Defense View